Antibodies

28 Jul 2009 Active Biotech's Cancer Project ANYARA Featured in Journal of Clinical Oncology
27 Jul 2009 Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
24 Jul 2009 RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PHASE II STUDY IN RELAPSED DLBCL
24 Jul 2009 OMT Announces a Breakthrough in the Development of a Novel Human Antibody Platform
24 Jul 2009 MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
24 Jul 2009 Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
24 Jul 2009 Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
24 Jul 2009 Ilaris® recommended for European approval as new biologic drug to treat a rare but serious group of auto-inflammatory diseases
24 Jul 2009 Merck KGaA Considers Appealing CHMP Opinion on Erbitux ATreatment for Non-Small Cell Lung Cancer
23 Jul 2009 First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion
22 Jul 2009 Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
20 Jul 2009 Nycomed announces FDA filing for Daxas® in COPD
20 Jul 2009 ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
20 Jul 2009 Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus
16 Jul 2009 Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting
16 Jul 2009 GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLD
15 Jul 2009 BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
15 Jul 2009 Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
15 Jul 2009 Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 Enzyme
15 Jul 2009 XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
13 Jul 2009 NovImmune successfully completes NI-0801 Phase I clinical study
13 Jul 2009 MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
10 Jul 2009 InNexus and Genhelix to Combine Antibody Development and Manufacturing Resources
09 Jul 2009 RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PIVOTAL CLL STUDY
09 Jul 2009 DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAX

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top